# A comprehensive view of the molecular features within the serum and serum EV of Alzheimer's disease

Jiayi Zhang<sup>1, †</sup>, Xiaoqin Cheng<sup>2, †</sup>, Anqi Hu<sup>1, †</sup>, Xin Zhang<sup>4</sup>, Meng Zhang<sup>1</sup>, Lei Zhang<sup>1</sup>, Jiawei Dai<sup>1</sup>, Guoquan Yan<sup>1</sup>, Huali Shen<sup>1, 5, \*</sup>, Guoqiang Fei<sup>3, \*</sup>

<sup>1</sup>Minhang Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.

<sup>2</sup>Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. <sup>3</sup>Department of Neurology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361000, China.

<sup>4</sup>Art school, Jiangsu University, Jiangsu, 212000, China.

<sup>5</sup>NHC Key Laboratory of Glycoconjugates Research, Fudan University, Shanghai, 200032, China. <sup>†</sup>These authors contributed equally

\*Corresponding authors: fei.guoqiang@zs-hospital.sh.cn (G.F.), shenhuali@fudan.edu.cn (H.S.).

# **Table of Contents**

### I. Supplemental figures and figure legends

## Figure S1. Schematic diagram of collection.

3D-printed integrated adapter collected the fractions from the qEV separation columns.

Figure S2. Software suites performance assessment in analyzing serum and serum EV proteomic data.

(A-C) The correlation of 39 serum samples from Spectronaut, peaks and DIANN (left to right).

(D-F) The correlation of 39 serum EV samples from Spectronaut, peaks and DIANN (left to right).

(G) The Missing value distribution of 39 serum samples from Spectronaut, peaks and DIANN (left to right).

(H) The Missing value distribution of 39 serum EV samples from Spectronaut, peaks and DIANN (left to right).

(I and J) Performance of proteome identification and quantification in three software.

#### Figure S3. External data comparation.

Comparation between differentially expressed protein groups in Figure3 and external data.

#### Figure S4. Diagnostic effect of the pairwise combination using top ten molecules.

(A-U) Diagnostic effect of the pairwise combination using top seven molecules from serum EV.

(V-X) Diagnostic effect of the pairwise combination using top three molecules from serum.

## **II. Tables and Supplemental tables**

 Table 1 Fraction collection protocol.

**Table 2** Details of DEPs with the AUC > 0.85.

Table S1 Clinical information.

Table S2 Protein groups from serum and serum EV identified by different database search software.

Table S3 Protein groups from serum and serum EV quantified by different database search software.

 Table S4 Quantitative results of serum protein groups.

Table S5 Quantitative results of serum EV protein groups.

Table S6 List of differentially expressed protein groups in serum and serum EV.

Table S7 Protein groups significantly associated with the incidence of AD from UKB.

# I. Supplemental figures and figure legends



**Figure S1. Schematic diagram of collection.** 3D-printed integrated adapter collected the fractions from the qEV separation columns.



**Figure S2. Software suites performance assessment in analyzing serum and serum EV proteomic data.** (A-C) The correlation of 39 serum samples from Spectronaut, peaks and DIANN (left to right); (D-F) The correlation of 39 serum EV samples from Spectronaut, peaks and DIANN (left to right); (G) The Missing value distribution of 39 serum samples from Spectronaut, peaks and DIANN (left to right); (H) The Missing value distribution of 39 serum EV samples from Spectronaut, peaks and DIANN (left to right); (I and J) Performance of proteome identification and quantification in three software.



**Figure S3. External data comparation.** Comparation between differentially expressed protein groups in Figure3 and external data.



**Figure S4. External data comparation.** (A-U) Diagnostic effect of the pairwise combination using top seven molecules from serum EV. (V-X) Diagnostic effect of the pairwise combination using top three molecules from serum.